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Further Studies on the Abnormal Insulin of Diabetes Mellitus 
Thesis directed by Professor Donough O’Brien
Insulin was extracted from pancreases obtained at autopsy 
from non-diabetic subjects (normal insulin) and from adult-onset 
diabetic subjects (diabetic insulin). Two pancreases were extracted 
with I M acetic acid, and the insulin containing fraction of the fluid 
portion of the extract was separated using Sephadex G 50. This 
fraction was lyophillised, then incubated with anti-insulin serum 
(guinea pig) and the insulin-anti-insulin complex separated using 
Sephadex G 50* Insulin was then dissociated from this complex using 
I M acetic acid, and separated from other protein with Sephadex G 50. 
This process yields only substances reacting with anti-insulin serum.
Other pancreases were extracted with a mixture containing 
ethanol, water and hydrochloric acid at pH< 1.5* The fluid portion 
of this extract was neutralised with ammonia and centrifuged. Insulin 
was precipitated from the supernate on addition of ethanol and diethyl 
ether. Catecholamines and cortico-steroids were not precipitated.
A mixture of uniformly labelled glucose (2 uc) together 
with normal or diabetic insulin in a total volume of 2 ml was injected 
intraperitoneally into each of 10 male Wistar rats. The mixture 
contained 800-1100 units of insulin per 2 ml, as determined by 
immunoassay. After 2 hours the rats were killed and their diaphragms 
removed. The diaphragmatic glycogen was isolated by digestion with 
hot 30% potassium hydroxide, followed by precipitation with 66%
ethanol. The activity of this glycogen was used as the measure
of glucose incorporation into glycogen.
Highly significant differences were found between the level 
of glucose in corporation following diabetic insulins and normal 
insulins.
This abstract of about 250 words is approved as to form and content.
I recommend its publication.
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INTRODUCTION.
By the beginning of the twentieth century experimental evidence 
had been gathered demonstrating that a disease state similar to 
human diabetes was produced by pancreatectomy in laboratory animals. 
This led to the proposal that an internal secretion of the pancreas 
was necessary for carbohydrate metabolism, and the name "insuline" 
was given to this substance by De Meyer in 1909*
The successful isolation of this substance by Banting and Best 
together with the description of its* clinical effects appeared to 
establish diabetes mellitus as due to a deficiency of insulin.
To confirm such a hypothesis it was necessary to demonstrate 
quantitatively a difference in the circulating levels of insulin 
between normal and diabetic subjects.
It was early early recognised that insulin was a protein, and 
would be present in the blood in such low concentration that it could 
not be measured by chemical techniques (I).
Development of techniques for measuring insulin.
To measure the comparatively high concentrations of insulin 
used in therapeutic preparations, biological assays were introduced. 
These utilize the fall in blood sugar or the induction of hypo­
glycemic coma in laboratory animals, and while satisfactory for this 
purpose are much too crude to determine insulin levels in biological 
fluids where the insulin level may be one millionth of that obtained 
in a therapeutic preparation.
2From observations that adrenaleetomised animals were more 
sensitive to insulin, Hemmingsen (1938) attempted to measure 
blood insulin by the induction of coma in such animals (2). He 
found values of less than 0.002 unit/ml of blood.
Gellhorn (19^ 1) introduced a much more sensitive preparation 
in hypophysectomised-adrenodemedullated mice (3). By measuring 
the fall of blood sugar following the injection of 1 ml of blood, 
he found levels of about 200 microunits/ml in normal subjects.
With this technique he was able to detect gross alterations in 
blood insulin level.
These techniques using whole animals are impractical in that 
numerous animals are required to obtain statistically significant 
results and their preparation often entails considerable mortality. 
Insulin bio-assay using rat tissue in vitro
Rat hemidiaphragms will continue to take up glucose from an 
incubating medium for several hours after removal from the animal.
Groen (1951) showed that such a preparation is sensitive to 
insulin, and could be used for measuring blood insulin (4). He 
reported that no insulin effect is obtained when blood from 
depancreatectomised animals, or from human diabetics in coma is 
used.
Although this assay, or refinements of it, is widely used, 
it is subject to criticism in that dilution of plasma results in 
a greater response than the original plasma (5). Pituitary hormones 
(oxytocin, vasopressin) also increase the rate of glucose uptake 
in this preparation.
3Martin (1958) introduced the isolated epididymal fat pad 
assay where the fat pads are incubated with glucose containing 
at the 1 carbon position. The -^C02 produced is a measure of the 
rate of glucose oxidation and is increased by insulin (6). Amounts 
of insulin as low as 10 microunits/ml will give a measurable increase 
in ^ C 02 production.
From the discordant values obtained for plasma insulin in 
normal subjects using these assays, it appears that they do not 
measure the same substance, and therefore comparisons of values 
between different investigators using different assay techniques 
is not valid (7).
Immunoassay of Insulin
The most recently introduced technique is the immunoassay 
(Fig. 1). Here, insulin displaces isotopically labelled insulin 
from a complex with anti-insulin serum. The amount of labelled 
insulin displaced is a measure of the unlabelled insulin added.
The amount of bound labelled insulin remaining was measured in 
the original technique by chromatoelectrophoresis on paper (8). 
Subsequently a second antigen-antibody system was introduced with 
the use of an antiguinea pig globulin which precipitates the insulin 
bound to anti-insulin (9). The assumption inherent in this technique 
is that only substances reacting with anti-insulin antibody will be 
detected. This antibody is prepared by the immunization of guinea 
pigs with insulin extracted from pancreas. It is possible that not all 
forms of circulating endogenous insulin will react with this antibody.
Furthermore, apparently high plasma insulin levels determined 
on undiluted plasma may show a sharp fall in calculated potency on
SIMPLIFIED SCHEME FOR THE DOUBLE ANTIBODY IMMUNOASSAY
5dilution. This effect can be overcome by the use of diluted plasma 
in the assay.
Complement has been found to interfere with precipitation of 
antibody-bound labelled insulin (10). This effect has also been 
attributed to lack of sufficient precipitating antibody (11). As 
most subjects receiving insulin develop anti-insulin antibodies, 
these would give a falsely high value in the immunoassay, if present 
in high concentration.
Estimates, by immunoassay, of the daily secretion of insulin 
agree well with the insulin requirements of totally pancreatec- 
tomised subjects (12). The extensive investigations of Yalow and 
Berson show that there is better correlation between immunoreactive 
insulin and biologically active insulin than is found by bio-assay. 
Insulin levels in Diabetes Mellitus
From clinical experience diabetics have been classified as 
"adult onset," when the disease manifests in later life, is sometimes 
associated with obesity, and the subject may not be insulin depen­
dent, and adequate control is often obtained with diet and oral 
hypoglycemic agents. "Juvenile" or "growth onset" diabetes appears 
before or during puberty. Most subjects with juvenile diabetes 
require insulin, and if untreated, progress to coma and death although 
milder cases similar to the adult onset disease occur.
The necessity for insulin parallels the severity of the 
clinical condition, so it would be expected that, if diabetes is due 
to deficiency of insulin, plasma insulin levels would correspond to 
insulin therapy requirements.
Berson, studying a group of normal subjects and adult onset 
diabetes found no difference between the two groups as measured by
immunoassay(12). Vallance-Owen, using the rat hemidiaphragm technique, 
found insulin in the plasma of adult onset dibetes, but none in a
'
group of juvenile diabetics (13)*
Prolonged fasting in normal humans results in the absence of plasmaI
insulin as determined by immunoassay, with an abrupt secretion into 
the plasma to above normal levels following glucose administration (1*0 ,
(15).
To accomodate these and other findings, several theories have been 
promulgated, and those germane to this work will now be briefly 
reviewed.
(1) "Synalbumin"
Vallance-Owen observed that plasma from juvenile diabetics, in addition 
to a lack of stimulatory effect upon glucose uptake by the rat diap­
hragm, inhibits the effect of added endogenous insulin (16). Under 
similar conditions plasma from normal subjects is without such inhib­
itory action.
When plasma from juvenile diabetics is subjected to protein 
fractionation, the inhibitory effect was associated with the albumin 
moiety. As (a) the inhibition does not result in values lower than 
those found in untreated diaphragms, and (b) the addition of greater 
amounts of insulin overcomes the inhibition, Vallance-Owen assumes 
that the inhibitory effect is a competition for binding sites between 
insulin and the inhibitor. This inhibitor was found in plasma from 
normal subjects, but at lesser concentrations-.
He has further demonstrated that this inhibitor— "Synalbumin"_
can be seperated from albumin. From it’s physicochemical and bio­
logical characteristics he concludes that Synalbumin is the isol­
ated B chain of insulin (17). Synalbumin is decreased from the
7plasma of hypophysectomised and adrenalectomised animals. Using the 
rat epididymal fat pad technique, Meade was unable to demonstrate an 
inhibitory action with albumin from severe diabetics (18). Also, 
there has been no report of an antagonistic effect of Synalbumin or 
B chain when given in vivo.
"Bound1' insulin
Antoniades has reported a series of findings on the nature of 
circulating insulin. By passage of the serum over a cation exchange 
resin, a portion of the serum insulin ("bound" insulin) is retained on 
the resin, the rest ("free" insulin) is unabsorbed (19). This bound 
insulin has a high molecular weight, while free insulin appears to 
correspond to crystalline insulin, or insulin prepared by acid-ethanol 
extraction of pancreas. Bound insulin is converted to free insulin 
by treatment with an extract of adipose tissue, or by extraction with 
acid-ethanol. Free insulin stimulates both the rat diaphragm and 
epididymal fat pad, while bound insulin acts upon the fat pad only 
(20. Bound insulin is not inactivated by exposure to anti-insulin 
sera, and migrates electrophoretically with gamma globulins, while the 
free form has the mobility of albumin or alpha globulin (21). Bound 
insulin is not measured in the immunoassay.
Berson was unable to demonstrate an increase in immunoassayable 
insulin in plasma from either adult onset diabetics or normal subjects 
after the plasma had been treated with adipose tissue extract. (12)
Cell Membrane Permeability
(a) Levine first showed that insulin increased the rate of 
transport of a non-metabolite into cells, usinggaLactose in evis­
cerated animals (22). Later he showed a similar effect with glucose (23).
8With increased substrate thus made available, it appeared 
reasonable to attribute the anabolic stimulation by insulin to the 
increased production of ATP. However, it has since been shown that 
increased uptake of amino acids by cells in response to insulin is 
independent of glucose (24-). Also, insulin will increase fat 
synthesis in cells without glucose as a source of energy (25).
(b) Krahl has proposed a mechanism which included all the effects 
known at that time (26). He considers that the action of insulin is 
due to interraction between the plasma membrane and insulin, resulting 
in a highly specific deformation of the membrane, rendering it more 
permeable.
(c) Rodbell has suggested that the effects of insulin upon 
isolated fat cells are dependent upon an intact cell membrane (27). 
Phospholipase C (phosphatidylcholine esterase) and insulin both 
stimulate glucose transport, fatty acid synthesis and. protein 
synthesis in such preparations. The degree of stimulation is 
proportional to the enzyme concentration to a maximum level. Insulin 
effect decreases with increasing enzyme effect. He suggests that 
insulin and phospholipase C both act upon the same parameter—  
membrane lipoprotein.
Elecher, using phospholipase A (phosphatidyl acyl hydrolase) 
demonstrated similar effects upon isolated fat cells (28). He 
also showed that, as with insulin, these effects of phospholipase A 
are inhibited by ethylmaleimide— a blocker of sulphydryl groups.
Encyme induction and inhibition
Weber describes a series of experiments concerning the effect 
of insulin and glucocorticoids upon the enzymes catalysing the 
four one-way reactions in gluconeogenesis (29). He shows that, in
rats, the activity of these enzymes is increased both by gluco­
corticoids and the induction of alloxan diabetes. Actinomycin D 
inhibits this rise in activity. Insulin reduces this activity in 
both diabetic and glucocorticoid treated rats to control levels.
He further reports that insulin is an inducer of pyruvate kinase, 
one of the key glycolytic enzymes (30). The level of pyruvate kinase 
falls sharply in rats made diabetic, returning to normal following 
insulin. This action of insulin is inhibited by actinomysin and 
ethionine.
Wool has investigated the stimulation by insulin of protein 
synthesis (31)* Utilizing a preparation of rat heart muscle micro- 
some s he found that insulin did not increase protein synthesis in 
vitro. However, when insulin was given to diabetic rats 1 hour 
before death a marked increase was found. He concludes that this 
action of insulin is consequential to the regulation of translation 
of messenger RM.
Abnormal insulin
Stimmler and Elliot estimated the disappearance rate of insulin 
from a medium incubated with rat hemidiaphragms (32). They found 
that insulin from diabetics persisted longer in the medium than 
insulin from nondiabetics or crystalline porcine insulin. At the 
time this was attributed to an inhibitor, but further evidence suggests 
that the insulin molecule itself is abnormal (33). Insulin was 
extracted by a technique which ensures a product reactive only to 
anti-insulin serum. Insulin, extracted by this technique from 
human diabetic sera, was more resistant to the action of rat 
muscle insulinase than insulin similarly extracted from normal sera,
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or porcine insulin. This suggests an alteration in the insulin 
molecule per se— an abnormal insulin.
This investigation was undertaken to extract insulin from 
pancreases of normal subjects and diabetics. The biological activity 
would be determined by measuring the increase in incorporation of 
labelled glucose into diaphragmatic glycogen in the intact rat. 
Significant differences in biological activity between normal and 
diabetic insulin would indicate that the diabetic insulin was different 
biologically, probably because of a different chemical structure.
EXPERIMENTAL
Except where otherwise indicated, all solutions are prepared 
using distilled water subsequently de-ionised by passage over 
Amberlite M.B.-3 resin. All chemicals are of "A.R." or "Reagent*1 
quality.
APPARATUS AND MATERIALS
Borate Buffer; 0.1M boric acid-sodium hydroxide pH 8.5*
Phosphate Buffer: 0.1M sodium dihydrogen phosphate-disodium 
hydrogen phosphate pH 7*3•
Bovine Serum Albumin: 30$ solution is diluted to 5$ albumin with 
phosphate buffer (phosphate BSA) or borate buffer (borate-BSA).
labelled Insulin: Diluted for use with borate-BSA to contain 
5 Ji units insulin in 50 pi. When newly received this amount gives 
2.5-3*0 x 103 c.p.m. ^^1. Replaced after one half life.
Normal Guinea Pig Serum: Sterile filtered serum. Diluted for use 
in immunoassay 1:130 with borate-BSA (N.G.P.S.).
Anti-Insulin Serum— Guinea Pig: Adult guinea pigs, randomly 
selected, were injected subcutaneously at 3 weekly intervals with 
P.Z.I. insulin, starting with 5 units, increasing to 25.
To reduce mortality from hypoglycemia, 4 ml of 50$ dextrose was 
given intraperitoneal concurrently. Two weeks after third injection, 
guinea pigs were bled by cardiac puncture.
Insulin injections were continued at three weekly intervals, 
bleeding two weeks after each injection.
Rabbit Anti-Guinea Pig Serum (RAGPS): Adult rabbits received 
normal guinea pig serum intravenously at two weekly intervals 
starting with 2 ml, subsequently 1 ml.
12
After the third injection they were bled by cardiac punture. 
Injections were continued at two weekly intervals, bleeding one 
week after each injection.
IkGlucose— U— ~ C: Specific activity greater than 2 mc/mM. This
ensured that no more than a tracer dose of glucose was received
by the test animals. All solutions for injection with glucose
were prepared from the freshly dissolved solid.
Liquid Scintillation Fluid (L.S.F.): 500 ml toluene
300 ml ethanol 
500 ml dioxane 
104 g naphthalene 
130 mg 1.4 bis (5 phenoxazolyl) 
benzene 
7.5 g 2:5 diphenyloxazole.
Optical Density: Measurements were made with a Beckman D.U.
spectrophotometer with #220 Gilford Absorbance Indicator. Quartz
cells with 10 mm light path used throughout.
pH: Leeds and Northrup #7401 direct reading pH meter with micro­
glass electrode.
125I activity: #314 E AutoGamma counter.
•^j'C and activity: #3000 Tri-Carb liquid scintillation counter. 
Centrifuges: (a) International SBVI— used in cold room at 4°.
(b) Sorval RC2 refrigerated high speed centrifuge.
Syringe Microburettes: were used to dispense 50 jul and 100 jil 
aliquots of reagents in the immunoassay.
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METHODS
Insulin Immunoassay (modified from Morgan and Lazarow) (9)
(a) Standardization of reagents.
(1) A.I.G.P. Guinea pig antiserum was diluted serially from 
1:250 to 1:5000 with borate— BSA.
Aliquots (50 pi) of these dilutions were added to tubes con­
taining 0.9 ml borate— BSA. Each dilution was set up in triplicate. 
12^l insulin— 5 P- units in 50 jil of borate— BSA was added to each 
tube, mixed, and stored at 4° for 18-24 hours.
RAGP (50-100 jJl as indicated) was added, mixed, then 50 >il 
NGPS added, mixed, and stored at 4° for 18-24 hours. Tubes were 
centrifuged at 3000 rpm for 15 minutes (SBVI). The supernates were 
decanted, and the walls of the tubes washed down with 0.5 ml of 1# 
bovine albumin in borate buffer.
Re-centrifuge and decant supernates.
Measure 125i activity of precipitates.
The dilution of AIGP which coraplexed 60-65$ of the 125l insulin, 
as shown by 60-65$ of the 125i activity added appearing in the 
deposit, is used in the immunoassay.
RAGP The volume of undiluted serum used in the immunoassay was 
the smallest which precipitated 50-70$ of the radioactivity from 
5 p units of insulin complexed with 50 ;ul of AIGP and 50 >il
of NGPS.
Procedure:
(a) 0.1 ml of serum or each standard solution is pipetted into 
0.1 ml of 5$ bovine albumin reagent. Each is done in trip­
licate .
(b) Add 0.05 ml labelled insulin reagent
(c) Add 0.05 ml anti-insulin guinea pig serum reagent
(d) Mix and allow to stand in the cold (4°) for 20-40 hours
(e) Add rabbit anti-guinea pig serum (amount added to be deter­
mined as described above under reagents)
(f) Add 0.05 ml normal guinea pig serum and mix
(g) Allow to stand at least 24 hours in the cold. Centrifuge 
for 15 minutes in the cold
(h) Pour off supernatant fluid into another labelled tube
(i) Wash precipitate with 0.5 ml of 1$ bovine albumin reagent, 
centrifuge for 15 minutes and puur supernatant fluid into 
the same tube as in step (h)
(j) Count the radioactivity of the precipitate and the super­
natant fluid separately.
(k) Calculate the ration of the total count (i.e. precipitate 
and SNF) to the count on the precipitate alone for each 
standard and test. Plot this ratio for the standards on 
linear graph paper. The calibration has been repeatedly 
shown to be a straight line up to 500/p u/ml with a coef­
ficient of variation of - 12$.
(1) The concentration for each test is determined.
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Blood glucose determined by glucose oxidase technique (3*0.
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ISOLATION OF PANCREATIC INSULIN
(a) Antibody complexed— gel filtered. Modified from Elliot (33)•
Principle♦ Pancreas is extracted with acid. The liquid 
extract is gel filtered to separate insulin from larger proteins.
The crude insulin thus obtained is complexed with anti-insulin and 
this complex separated by gel filtration. The complex is dis­
sociated with acid and gel filtered to separate insulin from anti­
bodies .
Technique.
1). The pancreas is weighed, coarsely sliced, and ext­
racted in a Waring blendor for 5 minutes, using 6 ml of I M acetic 
acid per gram of tissue.
2). The pH of the extract is checked, if necessary 
adjusted to pH 3*0-3*2 with glacial acetic acid.
3). The mixture is kept overnight at -18°.
4). After thawing, centrifuge at 12000 x g for 30 minutes. (RC2)
5). The intermediate fluid layer below the surface fatty 
layer is removed and kept. The deposit is re-extracted with I M 
acetic acid, using the same volume as in the initial extraction.
6). Re-centrifuge at 12000 x g for 30 minutes. Remove 
the intermediate layer, combine with the other intermediate layer 
and measure volume.
7). Add G 25 coarse Sephadex to the combined liquids 
to form a thin slurry.
8). Pour slurry into a Buchner funnel and allow liquid 
portion to drain and discard.
9). Wash the Sephadex 3 times with I M acetic acid, the
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volumes used being each 2/3 the volume of the combined liquid 
fractions (Stage 6).
10). Suck the Sephadex to dryness, combine all washings 
and bring to dryness in freeze drier.
11). Redissolve the powder in 50 ml of 0.5 M acetic acid, 
gel filter in a 3*8 x 50 cm column of G 50 coarse Sephadex, suspended 
in 0.5 M acetic acid.
12). Elute at 4° with 0.5 M acetic acid, collected in 10 ml 
fractions at 80-100 ml/hr. Measure the absorbance at 278 mu and 
plot readings against tube number.
13). Two distinct peaks are found. The contents of the 
tubes corresponding to the inter-peak space are combined and freeze- 
dried.
14). The dried material is dissolved in 50 ml of borate 
buffer and 3 »1 of anti-insulin serum added, mixed, and stored at 4° 
for 48 hrs.
15). Repeat gel filtration at 4° with this mixture, using 
Sephadex G 50 suspended in borate buffer with borate buffer as eluent.
16). Collect the material in the tubes giving peak at 278 mu, 
combine and freeze dry.
17). Dissolve the powder in 0.5 M acetic acid, gel filter at 
4° using G 50 Sephadex coarse suspended in 0.5 M. acetic acid, with 
0.5 M acetic acid as eluent.
18). Combine contents of the ten tubes following the protein 
peak and freeze dry.
19). Redissolve the powder in phosphate— BSA to ensure that 
no AIGP has been carried through into the final product, immunoassay is
performed using the product as sample, but without the addition of 
AIGP.
In the absence of AIGP no more than 1$ of the " ^ 1  insuiin 
activity is found in the precipitate.
(b) Acid-ethanol Extraction— Best et al (35)
Principle. Pancreas is extracted with acid-ethanol.
The fluid portion is brought to neutrality, precipitating proteins- 
but not insulin. Ethanol and ether are added, and hydrophillic 
compounds— including insulin— are precipitated.
1). The weighed pancreas is extracted for 5 minutes in
a Waring blendor with acid-ethanol-water (15 ml HC1, 750 ml ethanol 
250 ml water) using 6 ml mixture per gram of tissue.
2). Check pH, adjust if necessary to (2.0 keep overnight
at 4°.
3). Centrifuge at 6000 x g (RC2) for 30 minutes.
4). Collect supernate, re-extract deposit using the same 
volume of acid-ethanol-water as in stage (1), recentrifuge and 
combine supernates.
5). With continuous stirring, bring pH of combined super- 
nates to 7*5 using concentrated ammonia solution.
6). Allow 20 minutes for precipitate to flocculate, then 
centrifuge at 6000 x g for 15 minutes. Collect supernate and 
measure.
7). For each 9 ml of supernate, add, with continuous 
stirring 15 ml of ethanol, then 25 ml of diethyl ether per 9 ml 
of supernate.
8). Keep overnight at 4°, then gently detach the pre­
cipitate from walls of flask, allow to settle, aspirate and discard
18
supernate. Dry the deposit in a stream of air at room temperature.
9). Dissolve the deposit in 25 ml of 0.5 M acetic acid, 
bring pH to (3*5 if necessary with glacial acetic acid. Centrifuge 
at 6000 x g for 10 minutes, collect supernate and freeze dry.
10). Dissolve the powder in phosphate— BSA.
All pancreas extracts were stored at -18°.
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THE TEST OF BIOLOGICAL ACTIVITY from Rafaelson (36).
In a series of preliminary experiments designed to ascertain 
the optimum technique for this assay, the following protocol was 
established and was rigidly adhered to in all the tests performed. 
Male Wistor rats, aged three months and weighing 200 t 5 grams were 
used unless otherwise noted. In all but the firsttwo experiments 
they were obtained from Simonsen Laboratories, Minneapolis. The 
rats are used within three days of receipt, usually the day following 
arrival, and are allowed laboratory animal chow ad libitum until 
16-18 hrs. before test, when food is removed. Water is allowed 
at all times. To minimise the disturbance of metabolism due to 
stress, animals are kept overnight in the room in which the experi­
ment is carried out.* All tests were performed during the morning.
No anaesthetic is used.
Preparation of insulin-glucose injections.
The pancreas extract to be used is diluted with phosphate— BSA 
to give a concentration of 800-1000 p units/ml by immunoassay. This 
solution is assayed and frozen.
Both diabetic and normal pancreas extracts are treated 
identically. Immediately before the test a solution of ^ C  glucose 
in phosphate— BSA is prepared by dissolving the contents of a 50 ;ac 
ampoule in 25 ml of phosphate— BSA. Twelve millilitres of l2*C 
glucose solution is mixed with twelve millilitres of the pancreas 
extract, and aliquots are removed for immunoassay and ^ C  activity 
measurement.
Animal inoculation and diaphragm removal.
Using a blunted, smooth tipped #21 needle, two millilitres of 
* jkinsulin—  C glucose solution is injected intraperitoneally, 
slightly to the left of mid line and about halfway between the
20
sternum and pubis. Best results are obtained when the needle is 
directed about 1 cm laterally before penetration of the muscle.
Ater two hours the animal is killed with a blow to the head, and 
the abdomen opened longitudinally.
A careful search is made for evidence of needle perforation of 
the bowel, if present, results are not included.
The diaphragm in a segment of rib cage is removed and washed 
with running tap water at 8-10° or in a large volume of iced tap 
water. It is then placed on an ice cube, and the diaphragm muscle 
is dissected out, leaving the crura. This muscle is then washed 
twice in ice cold 0.1$ sodium fluoride in 0.9$ NaCl solution and 
blotted dry, then weighed to the nearest milligram on a torsion 
balance. The second fluoride wash fluid is kept.
The muscle is placed in a tube containing 2 ml of 30$ K0H 
solution at 93°•
The whole procedure from the blow to the head to the placing 
of the diaphragm in hot K0H takes from 3 to 3f minutes. The usual 
bio-assay involves two groups of ten animals, and initially the 
injections were performed at five-minute intervals, but this may be 
safely reduced to four minutes.
To ensure that there is no external contamination of the 
muscle the second wash fluid is assayed for radioactivity, if the 
content is more than twice background the results would be 
discarded. This did not happen with the technique described.
The isolation and measurement of glycogen.
(1) The diaphragm tissue is kept in the KOH solution at 93° for 
one hour, with occasional mixing to disperse the digested protein.
(2) Cool to room temperature, add 0.8 ml of anhydrous sodium 
sulfate solution, mix, add 6.4 ml of ethanol and mix again.
(3) Cool to -18°, and store at that temperature for one hour.
(4) Centrifuge at 9000 x g for 15 minutes.
(5) Decant supernate, drain over filter paper for 5 minutes.
(6) Wash walls of tube with 2 ml of 66$ ethanol, add 3 small 
glass beads and resuspend the precipitate.
(7) Centrifuge at 9000 x g for 15 minutes.
(8) Decant supernate, drain over filter paper for 5 minutes.
(9) Add 0.5 ml of water, mix thoroughly.
(10) Wash contents of tube into liquid scintillation counting 
vial, using 3 x 5 ml aliquots of LSF.
(11) Add Cab-o-Sil to the top of vial, shake vigorously, 
measure ^C  activity.
RESULTS
The following control experiments were performed to confirm 
the validity of the experimental procedures used in the test of 
biological activity.
1). To confirm that the precipitate washing removed all 
soluble radioactivity:
Three rats received 2 ml phosphate— BSA containing 2 pc
14C glucose intraperitoneally.
After two hours, the diaphragms were removed and treated as 
in the glycogen assay,—
A sample of: diaphragm digest after heating, 
the first supernate, and finally
the second supernate, were removed and their activity determined.
CPM l4C
0.1 ml digest 0.5 ml 1st supernate 0.5 ml second supernate 
Rat 1 137 83 38
Rat 2 493 72 44
Rat 3 522 86 53
Injected dose = 1,791*000 CFM/ml 
Average background = 44 CPM
This washing procedure is adequate for removing soluble radio­
activity.
2). While the washing procedure is adequate in removing 
soluble radioactivity, the possibility that labelled glucose 
was bound to the precipitate was tested for:
Two rats were killed, diaphragms removed and placed in hot 30# KOH. 
To each diaphragm was added immediately 0.1 ml of a glucose 
solution containing about 1 )ic in 0.1 ml.
The diaphragms were processed for glycogen. 
l^C glucose = 1,550,000 CFM/O.l ml.
Diaphragm Weight in mg CPM/diaphragm $ of added 
A 435 mg 1548 <0.1
B 387 2130 <0.1
C glucose is not carried through into the glycogen/L.S.F. 
mixture.
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Liquid scintillation counting may yield falsely high values 
from chemiluminescence, but as the tissue was digested immediately 
and the reagents throughout were identical this was not inves­
tigated .
Incorrectly low values may be obtained from quenching due to 
color or opacity.
This was investigated as follows:
Three rats were killed and their diaphragms removed and processed.
To each glycogen/L.S.F. mixture was added 0.1 ml of a glucose
T tlsolution, mixed, and the C activity measured immediately after 
mixing, and after 30 minutes.
Then, to one vial (Rat I) was added enough Cab-o-Sil to fill the 
vial, and well mixed.
To the second vial (Rat II) was added about twice the amount of 
Cab-o-Sil, and to the third vial (Rat III) about 3 times the original 
quantity.
14All 3 vials were checked for C level after 30 minutes. As control,
15 ml of L.S.F. plus 0.1 ml of the solution were mixed and the 
activity determined immediately and after 30 minutes.
lkC CPM $ Quench
Immediate Mixing After 30 Mins. After Cab-o-Sil After Cab-o-Sil
Rat I 35,993 28,642 36,013 2.3
Rat II 36,338 26,491 36,226 1.7
Rat III 36,015 26,997 36,319 1.7
Control 36,699 36,845
The results obtained show that quenching due to color is negligible, 
while that due to turbidity can be eliminated with Cab-o-Sil. The 
quantity of Cab-o-Sil is not critical.
Catecholamine recovery experiment:
10 grams of a normal pancreas were extracted with 60 ml of
l/j,acid-ethanol-water, and 500 ^ 1 of a solution of C ring labelled 
norepinephrine. The mixture was processed and the activity of 
the final extract determined.
CPM * C  added = 1.836.800
CFM * C  in extract = 47*320
$ of label in final extract = 2.5$
When 50 ;ul aliquots of the ^ C  norepinephrine solution were 
chromatographed on paper using a Butanol/acetic acid/water system, 
from 1-2$ of the activity did not travel with unlabelled norepine­
phrine. Therefore, it may be assumed that less than 1$ of the 
norepinephrine is extracted.
Cortisol-recovery experiment
10 grains of a normal pancreas were extracted with 60 ml of 
acid/ethanol/water after adding 250 ^  of a solution of ring 
labelled cortisol. The mixture was processed and the activity 
of the final extract determined.
CFM %  added = I.366.65O
CPM in extract = 5*670
$ of label in final extract = 0.4$
Blood glucose
Blood glucose levels were measured on rats receiving no 
insulin, and on rats receiving normal or diabetic insulin. Blood 
was drawn at injection and death.
BLOOD SUGAR 
(a) At Injection (b) At Death 
(1) Control Rats (2) Normal Insulin (850^ ^ 3) Diabetic Insulin (800
a b a b a b
75 93 64 73 59 69
77 94 62 73 62 76
64 71 60 78 65 78
78 96 58 76 62 66
57 60 51 69 68 73
53 66 52 65 58 65
62 76 50 68 51 70
6k 70 64 7 6 56 61
56 84 65 71 61 66
60 73 62 75 62 63
63 69 63 68 58 66
62 67 62 75 59 64
Mean Blood Sugars a b 52 64
Control 64 77 63 76
Normal Ins. 59 72 43 56
Diabetic-Ins. 59 68
Mean rise in blood sugar Control 19$
Normal Ins. 21$ 
Diabetic Ins. 19$
The rise in blood sugar is attributed to handling. No 
discernable effect on blood glucose from either normal or diabetic 
insulin.
GLUCAGON IMMJNO-ASSAY OF PANCREATIC EXTRACTS
EXTRACTS WERE DILUTED AS FOR ASSAY.
EXTRACT GLUCAGON mag/ml
#2 NORMAL 0
#1 DIABETIC 15
#2 DIABETIC 0
#3 DIABETIC 18
#4 DIAEETIC 174
#5 DIABETIC 10
This assay kindly performed by Dr. R. H. Unger.
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Normal Insulin Extracts
I)• Antibody complexed— Gel filtered insulin 
Normal #1 pancreas
Patient was 55 years old, male with no history or family 
history of diabetes mellitus.
Insulin concentration in final extract = 11,100 p. units/ml 
in 50 ml.
II). Acid ethanol extracted insulin 
Normal #2 pancreas
Patient was 68 years old, male, no history of diabetes mellitus 
or family history.
Insulin concentration in final extract = 500.000 )i units/ml in 
25 ml.
These rats received llfC glucose— (2 pc in 2 ml of phosphate—
BSA) only.
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ENDOGENOUS INSULIN ACTIVITY IN RATS
(TABLE I)
Rat # Weight
Weight
Diaphragm
Total ^C/ 
Diaphragm
* C  CPM/mg 
Diaphragm
1 190 535 1665 3.11
2 200 g 542 820 1.51
3 462 202 0.44
4 408 119 0.29
5 457 356 0.78
6 405 1330 3.28
7 393 264 0.67
8 396 86 0.22
9 441 78 0.18
10 495 373 0.75
11 426 443 1.04
12 393 477 1.21
13 523 271 0.52
14 479 1279 2.67
l^ C in 2 ml injectate = 1,798,000 CPM
n = 14 
x = 1.11 
1 ?  = 14.8 7 
S = 1.02
The rats' endogenous insulin concerts only a minimal of ^C 
glucose to glycogen ^ C.
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NORMAL INSULIN AT 700.1000 and 1500 MICROUNITS/DOSE 
(TABLE II)
Three groups of rats taken.
Gp I received approximately 700 )i units normal human insulin 
Gp II » «' 1000 » t i
Gp III " " 1500 »' " * "
14All received 2 ;ic C glucose.
INSULIN ASSAY EXTRACT DOSE INJECTED ^C GLUCOSE IN DOSE
I 695 1.417.660 CPM
II 1030 1120 1.378.830 CPM
III 1455 1310 1.485.960 CPM
Results
1 n X S.D.
I 10 9.198 2.70 72.89
II 10 1908 6.38 406.81
III 10 20.68 7.27 526.70
Si (I&II) = 5.16
S2 (II&III) = 7.21
*1 (I&II = 4.41
(II&III) = 0.276
pi (I&II) <0.001
P2 (II&III) <0.80)0.■70
At levels above 1100 /1 units/dose, diaphragm is saturated with 
insulin.
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TABLE II.
I.Diaphragm 
Weight
lJ*C /
Diaphragm
l^ C/mg
Diaphragm
IIDiaphragm 
1 Weight
14c/
Diaphragm
•^ C/mg
Diaphrag
354 2749 7.76 389 12,959 33.31
335 3004 8.97 371 6,838 18.43
339 2818 8.31 375 4,098 10.93
335 3345 9.98 327 8,648 26.45
40? 4841 11.89 311 7,440 23.92
327 2131 6.52 401 5,474 13.65
359 5302 14.77 436 6,156 14.12
354 2152 6.08 323 5,512 1?.06
395 2424 6.21 353 6,372 18.05
380 4366 11.49 319 5,677 17.90
III
417 10330 24.77
443 4689 10.58
355 9818 27.66
352 4129 11-73
355 5542 15.61
389 7785 20.01
340 6686 19.66
366 9032 24.68
313 10738 34.30
411 5581 13.58
Control rats received 2 ml each of a solution containing normal 
14pancreas insulin and C glucose.
Test rats received same mixture but with beef insulin B ehain*. 
added.
Insulin Assay (1) Extract (2) Dose Injected ^C In Dose 
Control 830 )x units 1180 p  units 1.365.290 CPM
Test 830 p. units 1200 /x units 1.389.300 CPM
S = 12.25
t = 0.601 - 15 degrees freedom 
p = <0.60>0.50
The concentration of B chain was 0.064 /ig in the 2 ml dose of 
insulin/glucose mixture. This is equivalent to 1600 microunits of 
insulin/dose. Immunoassay of B chain solution at this concentration 
gave a zero value— the B chain did not react with anti-insulin serum.
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NORMAL INSULIN AND NORMAL INSULIN WITH E CHAIN
(TABLE III)
♦Gift of Dr. J. Kirtley, Lilly Laboratories.
TAELS III
Control 
n = 9 
3? = 30.79 
S = 10.86
Test 
n = 8
x = 34.39 
s = 13.60
Diaphragm
Weight
CPM ^c/ 
Diaphragm
CPM lkC/mg 
Diaphragm
337 16558 49.13
389 14035 36.08
337 11345 33.66
347 8911 25.68
325 9231 28.40
400 9676 24.19
394 17011 43.17
335 7623 22.75
400 5618 14.04
357 17513 49.05
377 15842 42.02
370 9988 26.99
294 7739 26.32
333 17100 51.35
351 6999 19.94
303 4849 16.00
345 14994 43.46
Control rats received normal human insulin (#2 normal pancreas). 
Test Rats received crystalline beef insulin.*
BSSF INSULIN AND NORMAL HUMAN INSULIN
(TABLE IV)
Insulin Assay 
Control 
Test
Insulin Injected 
940 ji units/2 ml 
1000 p. units/2 ml
^C Injected 
1,753.480 CPM 
1,685,320 CPM
S = 21.43
t = 1.55 (17 degrees freedom) 
p = <0.20>0.10.
♦Gift of Dr. J. Kirtley, Lilly Laboratories
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Control 
n = 10 
x = 66.2 
S = 19.0
Test 
n = 9 
x = 50.9 
S = 21.6
TABLE IV
Diaphragm
Weight
CPM
Diaphragm
CPM l4C/mg 
Diaphragm
5^0 29592 58.2
545 25803 44.6
519 29452 58.1
378 23098 46.8
523 43620 87.1
705 45433 81.1
496 20847 40.4
571 37461 65-5
461 35124 81.7
449 52296 98.7
518 20823 46.3
578 20696 37-8
507 31807 61.3
493 33189 87.8
501 26036 49.8
560 26562 37.7
516 14032 28.3
572 14065 24.6
530 38125 84.9
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Pancreas Extract #1 f acid ethanol^.
(TABLE V)
Patient was 66 years old, male with moderate— Kimmelstiel- 
Wilson syndrome. Moderate diabetic for years, controlled on diet. 
Weight pancreas. 73 grams
Insulin content of final extract = 8500p  units/ml in 75 ml. 
Control pancreas Normal #2
Diabetic
Control
Mean Insulin/Dose 
990 )x units/ml 
920 )x units/ml
%  CPM/Dose 
1650640
1810350
S = 20.18
t = 4.64 (13 degrees freedom) 
p = <0.001
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TABLE V
Diaphragm
Weight
CPM l^ C/ 
Diaphragm
Control 648 32871
n = 8 561 16601
x = 58.4 518 15255
s = 25.1 591 24934
528 21008
455 40231
548 52023
605 51078
Test 479 10881
n = 7 441 4822
x = 10.5 490 2427
S = 6.0 535 7641
475 3647
367 6329
617 2129
50.7 
29.6 
29-5
49.8 
39-8
88.4
94.9
84.4
22.7
10.9
4.9 
14.2
7-7
9.9
3.4
CPM l2*C/mg
Diaphragm
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Pancreas extract #2 (acid ethanol).
(TABLE VI)
Patient was 43 years old, male, diabetes mellitus 8 years, 
controlled with low doses of insulin twice daily.
Weight of pancreas. 35 grams
Insulin content of final extract - 15.500 p. units/ml in 50 ml. 
Control pancreas Normal #2
Diabetic
Control
Mean Insulin/Dose
890 ^  u. 
IO65 )1 u. 1847560
1908130
C CFM/Dose
S = 10.02
t = 3*72 (17 degrees freedom) 
p = <0.01
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Diaphragm
Weight
Control 463
n = 9 488
x « 31.6 520
S ~ 12 • 1 538
486
520
558
558
612
Diabetic 507
n = 10 543
x * 14.5 590
S = 6.2 538
483
605
544
604
526
604
45.8 
16.5
24.8
41.3
53.4 
16.2
26.4 
32.0
27.5
7.2 
23.0 
10.2 
27.0
9.4 
15.2 
17.2 
10.8
8.4 
16.8
TABLE VI
CPM ^C/mg
Diaphragm
CPM l2ty 
Diaphragm
21198
8069
12888
22237
25935
8458
14771
17832
16993
3640
12402
6001
14504
4528
9232
9368
6487
4417
10143
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Diabetic Pancreas #3 (acid ethanol).
(TABLE VII)
Patient was 77 years old male. Diabetes Mellitus 20 years. 
Weight of pancreas. 50 grams
Insulin concentration in final extract = 500.000 ji units/ml in 50 ml 
extract.
Control pancreas. Normal #2
Diabetic
Control
Mean Insulin/Dose 
990 yy units 
1025 units
C CPM/Dose
1.873.990
1.931.980
S = 3.94
t = 3*40 (15 degrees freedom) 
p =<0.01
TABLE VII
Control 
n = 8 
x = 12.04 
S = 4.7
Diabetic 
n = 9
x = 5-53 
S = 2.6
Laphragm CPM ^ C/
Weight Diaphragm
429 9985
563 6727
445 6108
486 4938
516 6311
619 4487
559 5446
543 4423
587 1332
522 5654
588 3757
564 2773
512 1029
492 3357
620 2139
597 3215
531 4098
23.3
11.9 
13-7 
10.2 
12.2
7-2
9-7
8.1
2.3
10.9
6.4 
4.9 
2.0 
6.8 
3-5
5.4 
7.7
CPM l4C/mg
Diaphragm
Diabetic Pancreas #4 (acid ethanol)
(TABLE VIII)
Patient was 56 years old, female. Diabetes Mellitus 7 years 
on low doses of insulin.
Weight of Pancreas = 68 grams
Insulin concentration in final extract = 22.750 units/ml in 50 ml. 
Control pancreas = Normal #2
Mean Insulin/Dose l^ C CPM/Dose
Control 770 >1 units 1381440
Diabetic 840 units 1413460
S = 8.54 
t = 4.97
P = <0.001
4 3
TABLE VIII
Diaphragm
Weight
CPM 14C/ 
Diaphragm
CPM 1^C/mg 
Diaphragm
Control 401 16098 40.14
oHIfS 399 6807 17.06
X = 26.65 373 9198 24.65
s = 10.71 370 5374 14.52
336 13008 38.71
381 6073 15.93
374 5205 13.91
293 10049 34.29
400 12923 34.30
385 13488 35.03
Diabetic 317 788 2.49
n = 8 358 1877 5-24
x = 6.51 375 4345 11.58
s = 3.36 339 692 2.04
351 3423 9-75
342 2525 7-38
340 1804 5.30
378 3158 8.35
Diabetic Pancreas #5 (acid ethanol).
(TABLE IX)
Patient was 62 years old, male. Ten years history of Diabetes 
Mellitus, treated initially with insulin, subsequently with 
tolbutamide.
Weight of Pancreas = 9k grams
Insulin content of final extract = 69000 ji units/ml in 50 ml extract. 
Control, pancreas = Normal #2
Diabetic
Control
Mean Insulin/Dose 
890 )i units 
1150 ji units
l4C CPM/Dose 
1647800 
1623100
S = 8.36
t = 2.944 (17 degrees freedom)
TABLE IX
Diaphragm
Weight
CFM ^c/ 
Diaphragm
CPM ^C/mg 
Diaphragm
Control 545 12484 22.9
n =10 523 11635 22.2
x = 21.93 5^ 0 3127 5.8
S = 8.8 466 13113 28.1
55 0 5 002 9.1
531 10998 20.7
444 14336 32.3
444 14662 33.0
508 11860 23.3
Test 423 6911 16.3
n = 9 423 1255 3.0
x = 9.96 470 5647 12.1
S = 6.22 526 2164 4.1
518 8885 17.15
57 0 7096 12.4
494 8869 18.0
541 2960 5.5
450 476 1.1
Diabetic Pancreas extract #la (antibody complexed— gel filtered)
(TABLE X a+b)
Patient was 55 years old, female, diabetes 7 years, initially 
on insulin subsequently on orinase.
Weight of Pancreas = 82 grams
Insulin content of final extract = 950 p  units/ml in 50 ml.
Control pancreas = #1 Normal
Four groups of rats were inoculated on four different days. The 
CFM ^ C/mg diaphragm were corrected to a dose of 1.700.000/2 ml to 
avoid bias.
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Insulin Level/Dose (y. units) CPM/Dose
Diabetic Normal Diabetic Normal
990 1076 1767040 1747600
1080 1180 1847010 1789750
1050 1140 1725680 1667250
1152 1086 1623810 1529170
S = 18.92
t = 3*33 (48 degrees freedom) 
p = <0.01
TABLE X a
Control 
n = 25 
x = 42.17 
S = 21.9
Diaphragm
Weight
CFM 12|C/ 
Diaphragm
Corrected 
CFM 1 c/mg 
Diaphragm
485 16190 32.48
454 40227 86.22
489 39051 73-82
452 21325 45.76
473 12905 25.91
466 8590 17-48
429 9032 19.99
470 20281 44.01
420 26926 65.39
417 20325 49.72
4l6 31132 76.33
433 29199 68.78
403 33854 85.68
453 20325 45.76
384 16815 44.66
443 8553 21.43
467 13339 31.70
421 9880 26.05
463 11489 27.54
456 14254 26.98
434 9462 24.20
449 14809 36.61
403 15448 42.55
471 8724 20.56
409 5794 15.72
TABLE X b
. Corrected
Diaphragm CPM 14C/ CPM l^C/mg
Weight Diaphragm Diaphragm
Diabetic 497 10319 20.02
n = 25 589 20064 32.85
x = 24.35 498 10787 20.89
S = 15-3 414 20965 48.83
487 14205 28.13
5^8 2336 4.68
^50 6366 12.98
51^  2687 4.80
492 6957 13.93
516 24824 47.40
479 17181 35.34
412 9692 23.18
440 25185 56.39
9^7 25813 57.8O
462 14303 30.50
489 4453 9.53
*H8 5273 13.21
402 5891 15.34
3^6 6578 15.8O
512 2041 4.17
326 5944 19.21
2^3 13383 33-12
389 7372 19.84
0^3 8033 20.87
519 9984 20.14
DISCUSSION
(a) Validity of experimental procedures 
Glycogen extraction
Essentially this is the precipitation of glycogen with 66$ 
ethanol. Incubation of rat diaphragms with ^ C labelled glucose 
yields l^ C activity in lactate, glucose, alanine, maltose, carbon 
dioxide and glucose oligo saccharides (37)• Only glycogen and the 
higher oligo saccharides are insoluble in 66$ ethanol.
The hydrolysis of labelled ’'glycogen” derived by this technique, 
with subsequent formation of glucose phenylhydrazone yields specific 
activities comparable to the theoretical (36).
The control experiments confirm that the glycogen ^ C activity 
is not due to glucose ^C either from contamination by the injected 
material or from glucose l^ C in the muscle itself. The experiments 
on quenching show that the l^ C activity measured is a true represen­
tation of the l^ C activity present.
It is assumed, therefore, that this is a valid technique for 
the measurement of -^ C glucose incorporation into glycogen.
The test of biological activity
Stadie has shown that rat diaphragms will take up labelled 
insulin in vitro and that this activity cannot be removed by washing. 
When exposed to glucose 90 minutes after exposure to insulin and 
subsequent washing such diaphragms will incorporate glucose at an 
increased rate (38)*
Gamatt, in work confirming this, shows that there is a con­
tinuous uptake of ^lj insulin by isolated rat diaphragms; the rate 
of glucose uptake increasing with rise in insulin absorption.
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This uptake of glucose is not linear, and at a diaphragm insulin level 
of about 120 u units/l00 mg tissue there is no further increase in 
glucose uptake (39)•
When insulin is injected intraperitoneally into rats, it is 
without effect on tissues save those in direct contact with the 
peritoneal cavity (36)• This is shown by the differing patterns 
of labelled glucose uptake following intravenous or intraperitoneal 
injection together with a tracer dose of glucose. The insulin 
levels in the bio-assay fell between 800 and 1200 units per rat. If 
about 50$ of this was absorbed by the diaphragm there would be about 
80-120 u units insulin/100 mg tissue for most of the animals, the 
level at which diaphragm is saturated in vitro. The control experi­
ment using insulin at three different levels tends to confirm this 
by showing no increase in glucose uptake with an insulin dose 
of 1100 u units.
The test of biological activity is thus shown to be a sensitive 
indicator of insulin activity.
The pancreas extractions
Gel filtration, antibody complexed. With this treatment, insulin is 
freed from any combination with protein by acetic acid and gel 
filtration. It is then complexed with anti-insulin antibody. This 
complex will contain antibody, insulin and substances cross reacting 
with the antibody. The possibility that isolated B chains could 
be carried through with insulin was rejected by the demonstration 
that B chains are unreactive with the antiserum used.
This final extract contains only immunologieally pure 
insulin.
The initial extraction removes insulin from attachment to 
protein. Neutralisation of the acid ethanol extract precipitates 
protein, including gamma globulins. The final extract was crude, 
so it was necessary to determine if substances which would interfere 
in the test of biological activity or the immunoassay were present.
As shown by the control experiments, catecholamines and gluco­
corticoids, if present, are not precipitated by the addition of 
ether to the neutral acid-ethanol extract and so are not present 
in the final extract.
Acid alcohol extraction of pancreas results in quantitative 
yield of glucagon (40). As the B chain of insulin is also a poly­
peptide of approximately the same molecular weight it will also 
be recovered. As was shown in table II, B chain did not compete 
with insulin ih the test of biological activity.
Glucagon per se does not directly stimulate or inhibit the 
incorporation of glucose into muscle glycogen. Glucagon absorbed 
into the blood stream from the peritoneal cavity will stimulate 
pancreatic insulin release, thereby increasing the rate of muscle 
glycogen formation.
Immunoassay for glucagon performed on the acid-ethanol pan­
creatic extracts showed that the glucagon content of the normal 
pancreas extract was no greater than that of the diabetic pancreas 
extracts.
The increased rate of glycogen formation with the normal extract 
cannot, therefore, be attributed to glucagon.
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Acid-ethanol extraction
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Trypsin and chymotrypsin have been shown to have an insulin—  
like effect on the rat diaphragm in stimulating glycogen formation (41). 
Furthermore, chymotrypsin shows an insulin— like effect in the immuno­
assay, presumably by causing partial hydrolysis of the labelled 
insulin (42). Both of these enzymes are precipitated when the acid- 
ethanol extract is brought to neutrality, and so are not present 
in the final product.
The biological activity of insulin extracted from a non­
diabetic pancreas did not differ significantly in its biological 
activity of crystalline beef insulin. This was accepted as proof 
that the insulin itself had not been altered by the process of 
extraction.
A possible explanation for the difference in biological activity 
observed between normal and diabetic pancreases is that it is due to 
an artifact in the immunoassay. This would imply that something in 
the diabetic extract influences the immunoassay to a greater degree 
than does a normal pancreas extract. While this cannot be excluded, 
it is difficult to conceive the mechanism for such an effect, which 
has not been reported elsewhere.
All the diabetic pancreas extracts tested showed a highly 
significant difference in biological activity compared with a 
normal pancreas extract. This difference is assumed to reflect a 
change in the insulin molecule per se, perhaps leading to an altered 
state of aggregation. Some possible changes in the molecule which 
could account for the decreased biological activity will be briefly 
discussed.
54
(b) The Abnormal Insulin Molecule
It is well established that human insulin is a protein com­
prising two polypeptide chains joined by disulphide bonds.
An abnormal insulin must therefore differ in its’ amino acid 
composition by substitution or transposition of one or more amino 
acids.
Primary amino acid sequence
(1) Carboxy-terminal asparagine. Although 29 of the 51 
amino acids of the insulins so far described have at least two 
alternatives; with one possible exception all insulins so far 
reported have asparagine as the A chain carboxy-terminal amino 
acid (43). In the Lidley-Rollett model of the insulin molecule, 
an important role in the tertiary structure of insulin is attributed 
to this amino acid,— coupling to the arginine in position 22 of the 
B chain (44).
Several investigators have shown that insulin may exist as 
more than one isomeric form.
(a) Crystalline pork, beef and sheep insulins of full bio­
logical potency were subjected to countercurrent distribution (45). 
All showed a major component and several minor components. In 
each insulin two materials of equal biological activity were 
obtained— termed A and B— with the B component having one less 
amide group.
(b) Crystalline beef insulin when chromatographed on DEAE 
cellulose with elution at varying pH also showed two components (46).
Fraction I crystallised with zinc salts, and had full bio­
logical activity, while fraction II did not crystatallise with
zinc salts and had about 50$ of biological activity. These two 
fractions had different optical rotation, migrated differently 
in electrophoretic field but recombined at pH 8.5.
Fraction I possessed a higher positive charge.
(c) Two fractions, I and II were obtained when crystalline 
insulin (beef and pork) was subjected to either countercurrent 
distribution or partition chromatography (47). Fraction I had 
six free amino groups, while fraction II had five. The authors 
suggest that these components are the same as the A and B fractions 
of Craig and Harfenist (45).
As Craig and Harfenist did not give details of their bio­
assay procedure it is difficult to account for the discrepancy 
between their findings and those of Volini and Mitz (46).
Loss of asparagine from the A carboxy-terminal position results 
in loss of biological activity.
(a) Beef insulin from which the carboxy-terminal amino acids 
have been removed has forty percent of the biological activity
of unaltered insulin by the mouse convulsion assay (48). Loss 
of alanine only was without effect.
(b) Similar treatment yielded a product which had less than 
ten percent of biological activity by rat diaphragm and rabbit 
blood sugar techniques (49). Loss of alanine alone was without 
effect, but loss of asparagine alone gave the above findings.
Coupling of most of the free amino groups of insulin resulted 
in varying losses of activity (50). However, there is no indication 
as to which amino groups were blocked.
Although insulin from human diabetic pancreas was found to 
have the same quantitative amino acid composition as normal human
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pancreas insulin, it must be remembered that acid hydrolysis followed 
by column chromatography will not distinguish between asparagine and 
aspartic acid (51)*
More refined analysis of the abnormal insulin molecule may 
therefore show that asparagine is missing from the carboxy-terminal 
of the A chain, possibly substituted by aspartic acid.
(2) Substitution in the B chain
The greatly increased requirement for insulin in diabetic 
subjects with insulin resistance due to antibody formation may be 
reduced by the substitution of insulin from a different species. Thus, 
in clinical experience, the substitution of pork for beef insulin 
has this desired effect (52). As the difference between these 
insulins lies in their A chains, it may be assumed that the A 
chain is involved in antigenic activity.
This has been confirmed by the hybridisation of cod A chain 
with beef B chain and beef A chain with cod B chain. The former 
reacted only weakly with guinea pig anti-beef serum, but the latter 
reacted as strongly as pure beef insulin (53).
As the abnormal human insulin reacts with antisera, this suggests 
the possibility of an altered B chain with intact A chain.
(a) Incubation of insulin with trypsin results firstly in 
the loss of the carboxy-terminal amino acid of the B chain and 
subsequently loss of the adjacent seven amino acids as a group by 
hydrolysis of the B22-B23 peptide bond (49). The larger product, 
desheptapeptide insulin (DHA) was found to have about 15# of the 
biological activity of the original material, while the hep- 
tapeptide fragment was inactive.
(b) Other workers have been unable to confirm these findings 
with regard to biological activity (54,55)* They found DHA to
be biologically inactive using (as did the previous author) the 
rabbit-blood sugar assay. In addition, it was observed that the 
rate of release of heptapeptide followed the same kinetics as 
the loss of biological activity.
(c) DHA reacts fully with antisera prepared against the 
appropriate intact insulin (56).
From this evidence, the abnormality may be associated with 
the B23-B30 portion of the insulin molecule.
(3) Amino terminal glycine
Glycine is present as the amino terminal amino acid of the 
A chain in all insulins examined. Its * positive charge appears 
to be neutralised by the free carboxyl group on A4 (aspartic or 
glutamic acid), thus maintaining the structure of the molecule. 
Substitution of glutamine or asparagine at the A4 position 
presumably would distort the molecule.
While no evidence of such alteration exists, the effect of 
removal of the initial amino-terminal sequences of the A and B 
chains has been studied (57).
Insulin containing zinc resists the action of leucine amino- 
peptidase, while zinc free insulin is hydrolysed, with the probable 
loss of B1-B7 and A1-A6. Insulin treated in this manner lost 56$ 
of its activity as judged by mouse convulsion assay.
(4) Interchain leucine bonds
In the Lindley-Rollett structure, attachment between the side 
chains of the leucine molecules at Al6 and B15 and A13 and Bll by
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hydrophobic bonds is a major contribution to the tertiary structure.
Alteration of the structure could occur by substitution of 
these molecules by other amino acids with more polar side chains. 
Determination of the amino acid sequence of abnormal insulin will 
reveal such an abnormality.
While insulin exists as the monomer (6000 M.W.) in strongly 
acid solution and at alkaline pH, the dimer is found at weakly 
acid and neutral pH (58,59)* The dimer is the smallest form which 
contains zinc. It seems probable that insulin, in the physiological 
state exists as the dimer or possibly tetramer; but the techniques 
available for extraction of insulin do not allow confirmation of 
its’ state of polymerisation.
The attachments between the insulin molecules in the dimer 
are most logically through the BIO, BIO histidine side chains and 
the B13 B13 glutamic acid side chains with a zinc atom centrally 
coordinated.
Two further points of attachment are B17 Bl6 leucine hydro- 
phobic bonds and a B21 B1 salt link between the B21 glutamic free 
carboxyl and the B1 terminal amino group.
Obviously there are several points where an alteration 
insufficient to radically distort the structure of a monomeric 
insulin molecule could prevent its1 association into a dimer.
In this model of a dimer, the only significant possibility 
of interaction between the A chains is by Van der Waals forces 
acting between tyrosine residues Al4 Al4 (44,60).
Coupling of more than half the hydroxyphenyl groups results 
in marked biological inactivation, so interaction between the A 
chains may be an important factor in maintaining the insulin 
dimer as the biologically active form (50).
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The State of Association of Insulin
The data which have been presented lend themselves to two 
interpretations.
(1) That all the insulin extracted from the diabetic pancreases 
is abnormal insulin, or,
(2) That the abnormal insulin, is, in fact, a mixture of 
normal insulin and abnormal insulin with little or no biological 
activity.
If (1) is correct, it indicates that the diabetes of adult 
onset represents a homozygous condition. This is in line with 
the hypothesis advocated by Steinberg that diabetes results from 
the homozygous inheritance of a recessive gene of variable 
expression (6l). While this hypothesis is the most in accord 
with family studies, it is difficult to reconcile with the differing 
clinical pictures of juvenile and adult onset diabetes.
If (2) is correct, then this indicates that diabetes is 
inherited in a recessive manner, but that the adult diabetic is 
the heterozygous state, the juvenile diabetic being homozygous. (32,33) 
Assuming that plasma insulin level is a true indication of the 
pancreatic insulin production, the values which have been obtained 
on immunoassay of plasma from diabetics tends to support this 
hypothesis. Immunoassayable insulin is present at normal or 
elevated levels in asymptomatic juvenile diabetics and in diabetics 
of adult onset; but is present in low values only in the plasma 
of clinical juvenile diabetics. This is in contrast to the insulin 
levels obtained by bio-assay reporting low values in adult diabetics 
and complete absence of insulin in juvenile diabetics. The dif­
ference between the assays is a reflection of the reduced biological 
activity of abnormal insulin.
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(c) The Heredity of An Abnormal Insulin
It is then logical to postulate that the juvenile diabetic 
in the pre-clinical stage is producing sufficient abnormal insulin 
to maintain metabolic homeostasis, and becomes diabetic when insulin 
production falls behind metabolic requirements•
Indirect evidence to support this was obtained when two 
pancreases from juvenile diabetics were processed for insulin*
One was extracted by the acid-ethanol technique, the other by the 
antibody complex— gel filtration. In each case the insulin 
content of the entire final extract was less than 5000 microunits.
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CONCLUSION
While the evidence presented here for the existance of an 
abnormal insulin molecule in diabetes mellitus must be regarded 
as presumptive only, the considerable practical and theoretical 
importance of this concept will fully justify an investigation for 
the abnormality in the molecular structure of diabetic insulin.
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